STAAR Surgical Company

NasdaqGM:STAA Aktierapport

Börsvärde: US$1.3b

STAAR Surgical Framtida tillväxt

Future kriterier kontrolleras 4/6

STAAR Surgical förväntas öka vinsten och intäkterna med 71.6% och 11.8% per år respektive medan EPS förväntas växa med 72.6% per år.

Viktig information

71.6%

Tillväxttakt i vinsten

72.59%

Tillväxttakt för EPS

Medical Equipment vinsttillväxt15.3%
Intäkternas tillväxttakt11.8%
Framtida avkastning på eget kapitaln/a
Bevakning av analytiker

Good

Senast uppdaterad22 Apr 2026

Senaste uppdateringarna om framtida tillväxt

Results: STAAR Surgical Company Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 10
Results: STAAR Surgical Company Exceeded Expectations And The Consensus Has Updated Its Estimates

Recent updates

STAA: China Uncertainty And Leadership Transition Will Drive Bearish Reassessment

STAAR Surgical's updated fair value estimate shifts from $26.56 to $21.11 as analysts factor in revised Street targets. These include recent cuts to around $18 to $22 that reflect questions on China exposure and mixed near term visibility, despite some more supportive views emerging.

STAAR Surgical: Q1 Preliminary Revenues Justify Decision To Reject Alcon Bid

Apr 09

STAA: China Clarity And Post Alcon Reset Will Drive Future Re Rating

Analysts have trimmed price targets on STAAR Surgical to a range around $18 to $22, with a consensus reset of approximately $23.00, reflecting ongoing questions about China exposure, recent Q4 volatility, and limited near term visibility following the rejected Alcon deal. Analyst Commentary Recent Street commentary around STAAR Surgical centers on uncertainty, but there are pockets of optimism that readers should weigh alongside the more cautious views.

STAA: Ongoing China Uncertainty And Governance Turmoil Will Pressure Shares

Analysts have reduced the consolidated price target for STAAR Surgical to $22 from $28, reflecting lower assumptions for revenue growth and profit margins, a much higher future P/E multiple, and ongoing uncertainty around China and the company’s broader path forward. Analyst Commentary Recent Street research on STAAR Surgical points to a cautious tone, with multiple bearish analysts cutting price targets and reiterating neutral or underweight stances.

STAA: China Clarity And Post Alcon Reset Will Shape Future Upside Potential

Narrative Update on STAAR Surgical Our analyst price target for STAAR Surgical has been revised from $30.75 to $23.00 as analysts factor in recent target cuts, ongoing uncertainty around China and limited near term visibility highlighted in the latest research. Analyst Commentary Recent research on STAAR Surgical has leaned cautious, with multiple firms revising price targets lower and emphasizing uncertainty around the company’s outlook, particularly related to China and the failed Alcon transaction.

STAA: Post Deal Rejection Concerns Will Keep Shares Under Pressure

Analysts have reduced their average price targets on STAAR Surgical by high single digit dollar amounts to around $13.00. This reflects more cautious views on profit margins and valuation multiples after the failed Alcon deal and a series of Neutral and Underweight ratings.

STAA: Post Deal Collapse Uncertainty Will Pressure Shares Until Leadership Path Clears

Narrative Update on STAAR Surgical The analyst price target for STAAR Surgical has been reduced by US$8.75 following a neutral initiation, an Underweight resumption, and cautious commentary from several firms who highlight limited investor appetite until there is greater clarity on the company after the failed Alcon transaction. Analyst Commentary Recent Street research around STAAR Surgical has leaned cautious, with several firms highlighting valuation, execution, and growth risks following the failed Alcon transaction and the subsequent shareholder vote.

STAA: Post Alcon Deal Collapse And CEO Exit Will Cap Near Term Upside

Analysts have trimmed their fair value estimate for STAAR Surgical from US$17.41 to US$13.00, reflecting lower assumed revenue growth and a reduced future P/E multiple, alongside cautious commentary around limited buyer interest and uncertainty following the failed Alcon deal. Analyst Commentary Recent Street research has tilted clearly cautious, with several bearish analysts highlighting valuation pressure, deal uncertainty, and limited near term visibility on the business.

STAA: Failed Alcon Deal And Takeover Optionality Will Reshape Future Appeal

Analysts have lifted their fair value estimate for STAAR Surgical shares from US$28.00 to US$30.75, reflecting updated assumptions on growth, margins and future P/E multiples after recent debate over the failed Alcon deal and the limited near term appeal highlighted in recent research. Analyst Commentary Recent research has centered on the failed Alcon transaction, shareholder pushback on deal terms, and the limited near term appeal cited by several firms.

STAA: Amended Alcon Deal And Activist Push Will Drive Bullish Upside

Analysts have nudged their fair value estimate for STAAR Surgical higher from approximately $25.88 to $26.56. This reflects modestly stronger growth and margin expectations while acknowledging that any amended Alcon deal is unlikely to include a materially higher bid.

STAA: Merger Uncertainty Will Restrain Upside Despite Higher All-Cash Offer

Analysts have modestly raised their price target on STAAR Surgical from $16.00 to approximately $17.41 per share, citing slightly improved assumptions for long term revenue growth, profitability, and future valuation multiples, while they continue to monitor ongoing merger term discussions with Alcon. Analyst Commentary Bearish analysts highlight that the postponed shareholder meeting reinforces uncertainty around the timing and ultimate outcome of the proposed acquisition, which in turn clouds visibility on STAAR Surgical's standalone valuation.

STAA: Amended Merger Terms And Shareholder Opposition Will Guide Share Price Direction

Analysts have maintained their price target for STAAR Surgical at $25.88, citing limited expected upside due to ongoing merger negotiations and continued uncertainty regarding the acquisition terms. Analyst Commentary Market commentary surrounding STAAR Surgical’s ongoing merger negotiations reflects mixed analyst sentiment, with both cautious and optimistic perspectives regarding the company’s prospects and valuation.

STAA: Merger Discussions and Shareholder Opposition Will Shape Path Forward

Analysts have revised STAAR Surgical's price target downward to $16 from previous levels. They cite ongoing shareholder opposition to the proposed merger terms and uncertainty about a potential acquisition price.

Board Opposition And Postponed Vote Will Shape Acquisition Outcome In 2025

Analysts have raised their average price target for STAAR Surgical from $20 to $28 per share. They cite the strategic rationale and valuation of the proposed acquisition by Alcon as key drivers for the upward revision.

Introduction Of EVO+ Will Open Market Opportunities In 2025

Analysts have raised their price target for STAAR Surgical from $24.63 to $25.88. This reflects the impact of an increased acquisition offer and the perceived strategic value from Alcon's proposed purchase.

Introduction Of EVO+ Will Open Market Opportunities In 2025

Analysts have raised their price targets for STAAR Surgical primarily to reflect the proposed $28/share acquisition by Alcon, which sets a new benchmark valuation and limits further upside, resulting in a new consensus fair value of $24.14. Analyst Commentary Bullish analysts raised their price targets to align with the proposed $28/share acquisition price by Alcon.

Introduction Of EVO+ Will Open Market Opportunities In 2025

Driven by a significant improvement in net profit margin despite a higher discount rate, STAAR Surgical's consensus price target has increased from $19.20 to $22.11. What's in the News Alcon Inc.

Getting In Cheap On STAAR Surgical Company (NASDAQ:STAA) Might Be Difficult

Jul 04
Getting In Cheap On STAAR Surgical Company (NASDAQ:STAA) Might Be Difficult

Is STAAR Surgical Company (NASDAQ:STAA) Trading At A 37% Discount?

Apr 05
Is STAAR Surgical Company (NASDAQ:STAA) Trading At A 37% Discount?

Why Investors Shouldn't Be Surprised By STAAR Surgical Company's (NASDAQ:STAA) 26% Share Price Plunge

Feb 14
Why Investors Shouldn't Be Surprised By STAAR Surgical Company's (NASDAQ:STAA) 26% Share Price Plunge

STAAR Surgical Q4: Ongoing Challenges In China Masks Healthy Growth Elsewhere

Feb 12

STAAR Surgical: Growth Story Remains Intact Despite Some Challenges

Jan 31

STAAR Surgical Company's (NASDAQ:STAA) Earnings Haven't Escaped The Attention Of Investors

Nov 29
STAAR Surgical Company's (NASDAQ:STAA) Earnings Haven't Escaped The Attention Of Investors

Return Trends At STAAR Surgical (NASDAQ:STAA) Aren't Appealing

Oct 24
Return Trends At STAAR Surgical (NASDAQ:STAA) Aren't Appealing
User avatar

EVO ICL Technology Transforms Vision Care, Securing Major Growth And Market Share Expansion

STAAR Surgical's record sales and expansion in the diopter curve indicate strong global adoption of EVO ICL technology and potential for increased market share.

STAAR Surgical: Expecting A Re-Acceleration In Growth As Investments Materialize

Sep 05

Results: STAAR Surgical Company Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 10
Results: STAAR Surgical Company Exceeded Expectations And The Consensus Has Updated Its Estimates

STAAR Surgical Company's (NASDAQ:STAA) Popularity With Investors Is Clear

Aug 05
STAAR Surgical Company's (NASDAQ:STAA) Popularity With Investors Is Clear

The Returns At STAAR Surgical (NASDAQ:STAA) Aren't Growing

Jul 12
The Returns At STAAR Surgical (NASDAQ:STAA) Aren't Growing

Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?

May 27
Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?

Market Participants Recognise STAAR Surgical Company's (NASDAQ:STAA) Revenues Pushing Shares 30% Higher

Apr 26
Market Participants Recognise STAAR Surgical Company's (NASDAQ:STAA) Revenues Pushing Shares 30% Higher

STAAR Surgical Stock: I Don't See A Great Path Forward, Despite The Recent Surge

Apr 05

STAAR Surgical (NASDAQ:STAA) Shareholders Will Want The ROCE Trajectory To Continue

Mar 25
STAAR Surgical (NASDAQ:STAA) Shareholders Will Want The ROCE Trajectory To Continue

Prognoser för vinst- och omsättningstillväxt

NasdaqGM:STAA - Analytikernas framtida uppskattningar och tidigare finansiella data (USD Millions )
DatumIntäkterIntäkterFritt kassaflödeKassaflöde från rörelsenGenomsnittligt Antal analytiker
12/31/20283632431518
12/31/202733617403511
12/31/20263106153310
1/2/2026239-80-40-34N/A
9/26/2025231-96-40-30N/A
6/27/2025224-95-44-29N/A
3/28/2025279-71-31-12N/A
12/27/2024314-20-816N/A
9/27/2024341222647N/A
6/28/2024333171437N/A
3/29/2024326152141N/A
12/29/202332221-415N/A
9/29/202331020-34-14N/A
6/30/202330626-116N/A
3/31/2023295331735N/A
12/30/2022284401836N/A
9/30/2022279382241N/A
7/1/2022262342439N/A
4/1/2022243291933N/A
12/31/2021230283044N/A
10/1/2021217234455N/A
7/2/2021206213242N/A
4/2/2021179112836N/A
1/1/202116361321N/A
10/2/20201569211N/A
7/3/20201487413N/A
4/3/202015313717N/A
1/3/2020150141626N/A
9/27/20191429N/A18N/A
6/28/20191358N/A15N/A
3/29/20191296N/A11N/A
12/28/20181245N/A13N/A
9/28/20181184N/A12N/A
6/29/20181093N/A7N/A
3/30/2018971N/A6N/A
12/29/201791-2N/A3N/A
9/29/201788-2N/A2N/A
6/30/201784-5N/A0N/A
3/31/201784-6N/A3N/A
12/30/201682-12N/A1N/A
9/30/201681-13N/A-1N/A
7/1/201680-13N/A-1N/A
4/1/201678-12N/A-3N/A
1/1/201677-7N/A-2N/A
10/2/201573-8N/A-4N/A
7/3/201572-9N/A-5N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: STAA förväntas bli lönsam under de kommande 3 åren, vilket anses vara snabbare än sparkvoten ( 3.4% ).

Resultat vs marknad: STAA förväntas bli lönsam under de kommande 3 åren, vilket anses överstiga genomsnittet på marknaden.

Höga tillväxtresultat: STAA förväntas bli lönsam under de kommande 3 åren.

Intäkt vs marknad: STAA s intäkter ( 11.8% per år) förväntas växa snabbare än US marknaden ( 11% per år).

Hög tillväxtintäkter: STAA s intäkter ( 11.8% per år) förväntas växa långsammare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: Otillräcklig data för att avgöra om STAA s avkastning på eget kapital förväntas bli hög om tre år

Upptäck tillväxtföretag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/04/30 11:50
Aktiekurs vid dagens slut2026/04/30 00:00
Intäkter2026/01/02
Årlig intjäning2026/01/02

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

STAAR Surgical Company bevakas av 21 analytiker. 11 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Michael GormanBTIG
William PlovanicCanaccord Genuity
John YoungCanaccord Genuity